Study Supports ≥ 6 Months of DAPT After Endovascular Revascularization for Lower Extremity PAD
November 13, 2019—Sungsoo Choo, MD, et al published findings from an investigation to determine the optimal strategy for antiplatelet therapy in patients who have undergone endovascular revascularization for lower extremity peripheral artery disease (PAD). The study is available online in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.
The investigators concluded that dual antiplatelet therapy (DAPT) for ≥ 6 months after endovascular revascularization for lower extremity PAD was associated with decreased 5-year major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs).
The study involved an analysis of 693 patients with lower extremity PAD who were treated with different antiplatelet therapies from March 2008 to February 2013. The treatments included monoantiplatelet therapy (MAPT) and DAPT of various durations after endovascular revascularization and were classified into two groups (DAPT < 6 months; MAPT vs DAPT ≥ 6 months).
The primary outcomes were MACE and MALE rates, and the safety outcome was major bleeding.
As summarized in JACC: Cardiovascular Interventions, the investigators found the following results at 5-year follow-up:
- MACEs occurred less frequently in the DAPT for ≥ 6 months group than in the DAPT for < 6 months or MAPT group (17.3% vs 31.3%; hazard ratio, 0.44; 95% confidence interval, 0.3–0.65; P < .001).
- MALEs also occurred less frequently in the DAPT for ≥ 6 months group than the DAPT for < 6 months group or MAPT group (21.5% vs 43.7%; hazard ratio, 0.42; 95% CI, 0.3–0.58; P < .001).
- Major bleeding events were infrequent, with no signal toward harm with DAPT for ≥ 6 months.
Results were consistent after inverse probability-weighted adjustment and propensity score matching, reported the investigators in JACC: Cardiovascular Interventions.
advertisement
Related Articles
Top 5 Articles From October 2019
What’s New in Y-90?
Technical and procedural innovations in Y-90 radioembolization including existing and investigational next-generation technologies.
By Robert Abraham, MD, FRCPC, FSIR; Robert Lewandowski, MD, FSIR; Ripal T. Gandhi, MD, FSIR, FSVM; and David M. Liu, MD, FRCPC, FSIR
Transradial Access for Hepatic Oncologic Interventions
Considerations for choosing the right access equipment.
By Darren Klass, MBChB, MD, MRCS, FCRC, FRCPC; Anastasia Hadjivassiliou, MBBS, FRCR, FRCPC; and John Chung, MD, FRCPC
Contemporary Management of Pancreatic Cancer
An update on state-of-the-art minimally invasive therapies, including recent advances in surgery, radiation therapy, ablative options, and endovascular therapies.
By Ripal T. Gandhi, MD, FSIR, FSVM; Horacio Asbun, MD; Michael Chuong, MD; Filipe Kunzler, MD; and Govindarajan Narayanan, MD
Is It Time to End the Therapeutic Nihilism Toward Treating VTE in Cancer Patients?
Cases highlighting the potential for early benefit and improved quality of life and function associated with the use of FlowTriever and ClotTriever Systems in patients with cancer and VTE.
With Sirish A. Kishore, MD; and William C. Dillon, MD, FACC
Top Tips in Interventional Oncology
Clinical and technical insights into treating hepatocellular carcinoma, cholangiocarcinoma, renal cell carcinoma, lung cancer, bone cancer, and in the palliative care setting.
By Siddharth A. Padia, MD; Theodore Bryan, MD; Rebecca Bennett, MD; Nadine Abi-Jaoudeh, MD, FSIR, CCRP; Raul N. Uppot, MD; Robert Suh, MD; Paul I. Mallinson, MBChB, FRCR, FRCPC; Peter L. Munk, MDCM, FRCPC, FSIR, FFRRCSI (Hon); Miyuki Sone, MD; and Yasuaki Arai, MD, FSIR, FCIRSE
Top 5 from CIToday's Current Issue
Massive Thromboembolism, PFO, and Acute Limb Ischemia
By Moderator: Mohamad Alkhouli, MD
Panelists: Yashu Dhamija, MD; Abdul Moiz Hafiz, MD; Ankur Kalra, MD, FACP, FACC, FSCAI; and Anmar Kanaa’N, MD
Meeting the Challenge…
By Azeem Latib, MD
Compensation and Production Trends for Interventionalists
A look at MedAxiom’s annual report reflecting the continued evolution of the field in terms of physician demand and compensation agreements.
